PARMAX.BO · BSE
Parmax Pharma Limited
₹136.4
+1.00% (+₹1.35)
Prev. close
₹135.05
Volume
3,917
As of
21 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Parmax Pharma Limited
Parmax Pharma Limited operates in the pharmaceutical business in India. It manufactures and sells bulk drugs, drug intermediates, and specialty chemicals. The company was incorporated in 1994 and is based in Rajkot, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Umang Alkesh Gosalia
Headquarters
Rajkot
Website
parmaxpharma.comExchange
View on BSE ↗Key stats
Market cap
₹51.03 Cr
EPS (TTM)
₹-3.08
Beta (1Y · daily vs NIFTY 50)
0.28
Beta (5Y · monthly vs NIFTY 50)
0.79
EPS · quarter ended Jun 2026
₹5.88
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Debt/equity omitted where reported equity was zero or negative. Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹26.21 Cr | ₹18.25 Cr | ₹15.42 Cr | ₹11.05 Cr | ₹28.20 Cr | ₹12.11 Cr | |
| EBITDA | ₹3.50 Cr | ₹2.62 Cr | ₹2.31 Cr | ₹-3.42 Cr | ₹-89.17 L | ₹-3.65 Cr |
| ₹75.40 L | ₹14.10 L | ₹-10.41 L | ₹-5.75 Cr | ₹-2.09 Cr | ₹-4.16 Cr | |
| Diluted EPS | — | — | ₹-0.28 | ₹-34.56 | ₹-6 | ₹-11 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹17.61 Cr | ₹15.33 Cr | ₹18.75 Cr | ₹28.05 Cr | |
| — | — | ₹5.37 Cr | ₹5.91 Cr | ₹8.09 Cr | ₹12.06 Cr | |
| Stockholders' equity | — | — | ₹5.86 Cr | ₹10.53 L | ₹-1.99 Cr | ₹-6.15 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹33.31 L | ₹-19.63 L | ₹-65.64 L | ₹-2.36 Cr | |
| Investing cash flow | — | — | ₹-93.64 L | ₹-1.59 Cr | ₹-70.14 L | ₹-89.99 L |
| Financing cash flow | — | — | ₹-4.42 L | ₹1.43 Cr | ₹1.40 Cr | ₹3.81 Cr |
| Capital expenditure | — | — | ₹-93.64 L | ₹-1.59 Cr | ₹-70.14 L | ₹-89.99 L |
| End cash position | — | — | ₹40.68 L | ₹5.10 L | ₹9.03 L | ₹64.97 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| Parmax Pharma Limited | ₹51.03 Cr | ₹136.4 | — | — | — | — | -57.1% | +318.4% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 14
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Parmax Pharma acquirers lift stake to 58% in ₹35-per-share off-market deal
A consortium led by Dhiren Chandulal Shah and Sunil Chinubhai Shah acquired 1,152,450 shares of Parmax Pharma at ₹35 each in an off-market deal. This transaction increased their combined holding from 27.20% to 58.01%, giving them majority control of the company. The acquisition signifies a planned shift in Parmax Pharma's ownership.
Parmax Pharma Ltd Hits All-Time High of Rs 117.75 as Momentum Builds Across Timeframes
Markets Mojo · 1 month ago